[43] confirmed that NPAS2 played a tumour‐promoting gene in hepatocellular carcinoma (HCC) and upregulated NPAS2 was associated with aggressive clinical problems and poor prognosis, which was consistent with its role in acute myeloid leukaemia [44]. This evidence concerns the gene NPAS2 and hepatocellular carcinoma.